Biological Psychiatry: Semaglutide Significantly Reduces Heavy Drinking Days

Popular weight-loss drugs like semaglutide (Ozempic) may unexpectedly help people drink less: taking them markedly reduced the number of heavy drinking days. However, the picture regarding alcohol cravings itself turned out to be less straightforward. A data review was published in the journal Biological Psychiatry.

The medications in question belong to the GLP-1 receptor agonist class, which were originally developed to treat diabetes and obesity but are increasingly being studied for addiction. Danish researchers synthesized results from several trials. In the largest study—involving 108 individuals with obesity—semaglutide reduced the proportion of heavy drinking days by 41.1 percentage points from baseline, compared to 26.4 points in the placebo group—a 13.7 percentage point greater reduction.

At the same time, the researchers make an important caveat: drinking less is not the same as craving less. In one trial, while the number of heavy drinking days dropped, laboratory-measured alcohol cravings showed no significant difference compared to placebo, even though participants did report a weakened drive to drink in their daily lives.

The mechanism is thought to involve the drugs acting not only on appetite, but also on the brain's reward system by dampening the pleasure derived from alcohol. This represents a promising direction: effective treatments for alcohol dependence are scarce, and the prospect of repurposing existing medications is generating substantial interest. However, current data remain fragmented and sample sizes small, making it premature to label semaglutide a cure for alcoholism—larger, dedicated clinical trials are needed.

Alcohol dependence remains one of the most common and difficult-to-treat conditions, with few available medications that do not work for everyone. This makes the idea of repurposing already approved, well-studied drugs particularly appealing. If the benefits of semaglutide for alcohol misuse are confirmed in large-scale trials, it could significantly expand the medical toolkit for clinicians.

Follow NEWS.am Medicine on Facebook and Twitter